JACC. CardioOncology (Sep 2020)

Cardiac Disease in Childhood Cancer Survivors

  • Jan M. Leerink, MD,
  • Esmée C. de Baat, MD,
  • Elizabeth A.M. Feijen, PhD,
  • Louise Bellersen, MD,
  • Elvira C. van Dalen, MD, PhD,
  • Heynric B. Grotenhuis, MD, PhD,
  • Livia Kapusta, MD, PhD,
  • Wouter E.M. Kok, MD, PhD,
  • Jacqueline Loonen, MD, PhD,
  • Heleen J.H. van der Pal, MD, PhD,
  • Saskia M.F. Pluijm, PhD,
  • Arco J. Teske, MD, PhD,
  • Annelies M.C. Mavinkurve-Groothuis, MD, PhD,
  • Remy Merkx, MD,
  • Leontien C.M. Kremer, MD, PhD

Journal volume & issue
Vol. 2, no. 3
pp. 363 – 378

Abstract

Read online

Cardiac diseases in the growing population of childhood cancer survivors are of major concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy continues to be relevant in the modern treatment era. Mitoxantrone has emerged as an important treatment-related risk factor and evidence on traditional cardiovascular risk factors in childhood cancer survivors is accumulating. International surveillance guidelines have been developed with the aim to detect and manage cardiac diseases early and prevent symptomatic disease. There is growing interest in risk prediction models to individualize prevention and surveillance. This State-of-the-Art Review summarizes literature from a systematic PubMed search focused on cardiac diseases after treatment for childhood cancer. Here, we discuss the prevalence, risk factors, prevention, risk prediction, and surveillance of cardiac diseases in survivors of childhood cancer.

Keywords